• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

    7/17/24 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business updates.

    The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

    About Sage Therapeutics

    Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240717928127/en/

    Get the next $SAGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Germano Geno J

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:14:14 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Golumbeski George

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:14:04 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Frates James M

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:13:57 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    SEC Filings

    See more
    • SEC Form SC TO-C filed by Sage Therapeutics Inc.

      SC TO-C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 5:26:56 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC14D9C filed by Sage Therapeutics Inc.

      SC14D9C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 5:20:11 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by Sage Therapeutics Inc.

      SC TO-C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 11:40:45 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

      For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

      8/8/23 9:34:19 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

      For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

      8/4/23 6:50:31 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care